AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20044497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 20044497 — intervention group
Group type: EXPERIMENTAL
Intervention: Press-fit fixation (P)
Number of subjects: 20
Study 18198064 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV) procedure
Number of subjects: 178
Study 18198064 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV procedure
Number of subjects: 178
Study 16981914 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ms initial drive train
Number of subjects: 50
Study 16981914 — intervention group
Group type: COMPARATOR
Intervention: 600 ms initial drive train
Number of subjects: 50
Study 16981914 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall induction rates
Number of subjects: 50
Study 14556870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone SR 425 mg twice daily
Number of subjects: 0
Study 14556870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone SR 325 mg twice daily
Number of subjects: 0
Study 14556870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone SR 225 mg twice daily
Number of subjects: 0
Study 14556870 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 0
Study 10758989 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ratio (CR) 6:1
Number of subjects: 21
Study 10758989 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ratio (CR) 10:1
Number of subjects: 21
Study 10758989 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ratio (CR) 16:1
Number of subjects: 21
Study 10758989 — intervention group
Group type: COMPARATOR
Intervention: Uncompressed images
Number of subjects: 21
Study 8836744 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based upper-arm exercise program (3 exercises, 5 times a week for 8 weeks)
Number of subjects: 20
Study 8836744 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly contact to equalize attention)
Number of subjects: 20
Study 1389953 — intervention group
Group type: EXPERIMENTAL
Intervention: Medifoxamine 300-1000 mg
Number of subjects: 0
Study 1389953 — intervention group
Group type: COMPARATOR
Intervention: Timolol 20 mg
Number of subjects: 0
Study 4073076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanate potassium
Number of subjects: 20
Study 4073076 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 20
Study 30711522 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (43.5 Gy in 15 fractions over 3 weeks)
Number of subjects: 820
Study 30711522 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (50 Gy in 25 fractions over 5 weeks)
Number of subjects: 820
Study 30711522 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 820
Study 30711522 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy
Number of subjects: 820
Study 29366432 — intervention group
Group type: EXPERIMENTAL
Intervention: MYLO program
Number of subjects: 213
Study 29366432 — intervention group
Group type: COMPARATOR
Intervention: ELIZA program
Number of subjects: 213
Study 27140403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated call centre (SOS-HAE) for management of HAE attacks
Number of subjects: 200
Study 27140403 — intervention group
Group type: COMPARATOR
Intervention: Usual practice for management of HAE attacks
Number of subjects: 200
Study 24139860 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% of habitual number of chews (HNC)
Number of subjects: 18
Study 24139860 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% of habitual number of chews (HNC)
Number of subjects: 18
Study 24139860 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% of habitual number of chews (HNC)
Number of subjects: 18
Study 24139860 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% and 200% of habitual number of chews (HNC)
Number of subjects: 18
Study 23067317 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing 7-day triple therapy (Levo triple)
Number of subjects: 345
Study 23067317 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sequential therapy (SST-10)
Number of subjects: 345
Study 23067317 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing sequential therapy (Levo-ST-10)
Number of subjects: 345
Study 23067317 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 345
Study 19417588 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC-201 (Hemopure)
Number of subjects: 27
Study 19417588 — intervention group
Group type: COMPARATOR
Intervention: PRBC
Number of subjects: 27
Study 18630547 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture compound anesthesia (electroacupuncture combined with intramuscular injection of Pethidine)
Number of subjects: 316
Study 18630547 — intervention group
Group type: COMPARATOR
Intervention: Simple Pethidine (intramuscular injection)
Number of subjects: 316
Study 18630547 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture compound anesthesia
Number of subjects: 316
Study 18630547 — intervention group
Group type: COMPARATOR
Intervention: Simple Pethidine
Number of subjects: 316
Study 16195767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid Replacement Therapy plus antioxidants
Number of subjects: 0
Study 16195767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11830625 — intervention group
Group type: EXPERIMENTAL
Intervention: PMCT with segmental hepatic artery embolization and temporary interruption of hepatic venous flow
Number of subjects: 31
Study 11830625 — intervention group
Group type: COMPARATOR
Intervention: PMCT with segmental hepatic artery embolization only
Number of subjects: 31
Study 10363733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400-mg loading dose followed by 200 mg once daily)
Number of subjects: 603
Study 10363733 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (750 mg twice daily)
Number of subjects: 603
Study 10363733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 603
Study 10363733 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 603
Study 8545460 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16
Study 8545460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1778879 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g ceftriaxone iv once daily for three days
Number of subjects: 59
Study 1778879 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g ceftriaxone iv once daily for three days
Number of subjects: 59
Study 1778879 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 3 g daily in divided doses for two days followed by 2 g daily for 12 days
Number of subjects: 59
Study 6980231 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg oxaprozin (600 mg twice daily)
Number of subjects: 29
Study 6980231 — intervention group
Group type: EXPERIMENTAL
Intervention: 3900 mg aspirin (975 mg four times a day)
Number of subjects: 29
Study 6980231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31296647 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 957
Study 31296647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (diet, physical activity, behavior modification)
Number of subjects: 957
Study 31296647 — intervention group
Group type: EXPERIMENTAL
Intervention: N-ethyl-perfluorooctane sulfonamido acetic acid
Number of subjects: 957
Study 31296647 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorodimethylhexane sulfonic acid
Number of subjects: 957
Study 29758380 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (BI) delivered via computer or therapist
Number of subjects: 475
Study 29758380 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (BI)
Number of subjects: 475
Study 27109630 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization
Number of subjects: 138
Study 24490712 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence and work group (n = 16)
Number of subjects: 46
Study 24490712 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-only group (n = 15)
Number of subjects: 46
Study 24490712 — intervention group
Group type: COMPARATOR
Intervention: No-voucher control group (n = 15)
Number of subjects: 46
Study 23265228 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week group intervention
Number of subjects: 116
Study 23265228 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 116
Study 23265228 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis of intervention
Number of subjects: 116
Study 20537469 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal compression pressure garment therapy
Number of subjects: 0
Study 20537469 — intervention group
Group type: COMPARATOR
Intervention: Low compression pressure garment therapy
Number of subjects: 0
Study 17998496 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 458
Study 17998496 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) shock
Number of subjects: 458
Study 17998496 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 458
Study 14693987 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (4 glasses of whisky, 40 g ethanol daily)
Number of subjects: 23
Study 14693987 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 23
Study 14693987 — intervention group
Group type: COMPARATOR
Intervention: Control (tap water)
Number of subjects: 23
Study 12401630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 60
Study 12401630 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 60
Study 12563776 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 6 mg/kg once every 2 weeks for 4 times
Number of subjects: 780
Study 12563776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 8547549 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (55 micrograms/kg) anesthesia
Number of subjects: 30
Study 8547549 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (55 micrograms/kg) anesthesia + thoracic epidural analgesia
Number of subjects: 30
Study 8547549 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl (15 micrograms/kg) anesthesia + thoracic epidural analgesia
Number of subjects: 30
Study 8547549 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 30
Study 2230578 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCh (local ultra‐high frequency hyperthermia in combination with radiotherapy and chemotherapy)
Number of subjects: 54
Study 2230578 — intervention group
Group type: COMPARATOR
Intervention: RCh (radiotherapy and chemotherapy)
Number of subjects: 54
Study 773416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic factor VIII therapy (infusions given once weekly to achieve a post-infusion plasma concentration of at least 0.25 I.U./ml)
Number of subjects: 9
Study 31144661 — intervention group
Group type: COMPARATOR
Intervention: White light magnification alone
Number of subjects: 249
Study 31144661 — intervention group
Group type: EXPERIMENTAL
Intervention: BLI-contrast magnification
Number of subjects: 249
Study 31144661 — intervention group
Group type: EXPERIMENTAL
Intervention: BLI-bright magnification
Number of subjects: 249
Study 28527129 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (240 µg/kg/day) + G‐CSF (filgrastim, 400 µg/m2/day) for 4 days
Number of subjects: 14
Study 28527129 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF alone (G group)
Number of subjects: 14
Study 25125385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) alone for 7 days
Number of subjects: 20
Study 25125385 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) plus Hydroxychloroquine (HCQ)
Number of subjects: 20
Study 25125385 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) alone
Number of subjects: 20
Study 25125385 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) plus Clopidogrel (CLOP)
Number of subjects: 20
Study 25125385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) alone or in combination with ASA
Number of subjects: 20
Study 23149295 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center hemodialysis 6 times per week
Number of subjects: 299
Study 23149295 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nocturnal hemodialysis 6 times per week
Number of subjects: 299
Study 23149295 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (both trials)
Number of subjects: 299
Study 23149295 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (Daily Trial)
Number of subjects: 299
Study 23149295 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (Nocturnal Trial)
Number of subjects: 299
Study 21562238 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplement (15 mg zinc as ZnSO4)
Number of subjects: 132
Study 21562238 — intervention group
Group type: COMPARATOR
Intervention: Control (200 g/d of wheat bread fortified with iron and folic acid, no zinc)
Number of subjects: 132
Study 21562238 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate zinc fortification (7.5 mg zinc as ZnO)
Number of subjects: 132
Study 21562238 — intervention group
Group type: EXPERIMENTAL
Intervention: High zinc fortification (15 mg zinc as ZnO)
Number of subjects: 132
Study 19221190 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (1,000 mg of elemental calcium carbonate and 400 IU of vitamin D(3) daily)
Number of subjects: 36282
Study 19221190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 19221190 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation
Number of subjects: 36282
Study 16996354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelican multibite forceps
Number of subjects: 6
Study 16996354 — intervention group
Group type: COMPARATOR
Intervention: Radial Jaw 3 (RJ3) double-bite forceps
Number of subjects: 6
Study 12643319 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton (hydroxyethyl rutosides) 1 g twice daily for 3 days (2 days before the flight and the day of the flight)
Number of subjects: 164
Study 12643319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 164
Study 12060966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water bath at 39.5 degrees C
Number of subjects: 12
Study 10085710 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensinogen gene m235t polymorphism, ACE gene I/D polymorphism, ACE gene Pst I RFLP polymorphism
Number of subjects: 246
Study 10085710 — intervention group
Group type: COMPARATOR
Intervention: Control group (130 healthy pregnant women)
Number of subjects: 246
Study 7981011 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 2.5 mg p.o.
Number of subjects: 24
Study 7981011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2659289 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam + Cefotaxime (AZ + CE)
Number of subjects: 33
Study 2659289 — intervention group
Group type: COMPARATOR
Intervention: Amikacin + Cefotaxime (AM + CE)
Number of subjects: 33
Study 790893 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 21
Study 790893 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study 31311465 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT+EVT
Number of subjects: 240
Study 31311465 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT alone
Number of subjects: 240
Study 31311465 — intervention group
Group type: COMPARATOR
Intervention: nonreperfusion care
Number of subjects: 240
Study 30028098 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous endometrial cell coculture (AECC)
Number of subjects: 134
Study 30028098 — intervention group
Group type: COMPARATOR
Intervention: Traditional in vitro fertilization (IVF)
Number of subjects: 134
Study 30028098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AECC and control)
Number of subjects: 134
Study 26056202 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFT Wellness Program (multifactorial fall-prevention intervention)
Number of subjects: 0
Study 26056202 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 26056202 — intervention group
Group type: COMPARATOR
Intervention: Administrative control group
Number of subjects: 0
Study 24067395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous myo-inositol at 60 mg/kg
Number of subjects: 0
Study 24067395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous myo-inositol at 120 mg/kg
Number of subjects: 0
Study 24067395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21802038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hold-relax proprioceptive neuromuscular facilitation stretching (HR-PNF)
Number of subjects: 30
Study 21802038 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 30
Study 21802038 — intervention group
Group type: COMPARATOR
Intervention: Control (left leg, no intervention)
Number of subjects: 30
Study 19515113 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription drugs and dietary supplements
Number of subjects: 3070
Study 19515113 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription drugs
Number of subjects: 3070
Study 19515113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 3070
Study 19515113 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen preparations
Number of subjects: 3070
Study 19515113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs, thyroid drugs, and estrogens
Number of subjects: 3070
Study 19515113 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs for diabetes mellitus
Number of subjects: 3070
Study 19515113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins, glucosamine and chondroitin, and echinacea
Number of subjects: 3070
Study 17607956 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (increased cereal consumption)
Number of subjects: 57
Study 17607956 — intervention group
Group type: COMPARATOR
Intervention: Diet V (increased vegetable consumption)
Number of subjects: 57
Study 14982510 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 36
Study 14982510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11275667 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional approach
Number of subjects: 152
Study 11275667 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-conventional approach
Number of subjects: 152
Study 11275667 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atraumatic Restorative Treatment (ART)
Number of subjects: 152
Study 11275667 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups combined
Number of subjects: 152
Study 11275667 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 152
Study 9210004 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 40
Study 9210004 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 40
Study 29925421 — intervention group
Group type: EXPERIMENTAL
Intervention: S-amlodipine (2.5 mg) plus chlorthalidone (25 mg)
Number of subjects: 170
Study 29925421 — intervention group
Group type: COMPARATOR
Intervention: S-amlodipine (2.5 mg) plus telmisartan (40 mg)
Number of subjects: 170
Study 26791992 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized medication reviews conducted by expert teams
Number of subjects: 150
Study 24771015 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-fortified drinking skim milk (Zn-FMilk) for 2 months
Number of subjects: 0
Study 24771015 — intervention group
Group type: COMPARATOR
Intervention: Standard non-fortified milk (No-FMilk)
Number of subjects: 0
Study 22508964 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusine (4% succinylated gelatine)
Number of subjects: 25
Study 22508964 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven (6% hydroxyethyl starch)
Number of subjects: 25
Study 20119816 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg, 3 times daily) with dietary treatment
Number of subjects: 21
Study 20119816 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment only
Number of subjects: 21
Study 16460484 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole, amoxicillin, and minocycline
Number of subjects: 167
Study 16460484 — intervention group
Group type: COMPARATOR
Intervention: rabeprazole, amoxicillin, and clarithromycin
Number of subjects: 167
Study 16460484 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole, minocycline, and metronidazole
Number of subjects: 167
Study 16460484 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole, minocycline, and faropenem
Number of subjects: 167
Study 14722033 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DC)
Number of subjects: 311
Study 14722033 — intervention group
Group type: COMPARATOR
Intervention: Vindesine plus cisplatin (VdsC)
Number of subjects: 311
Study 11455735 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed system (CS) suctioning
Number of subjects: 14
Study 11455735 — intervention group
Group type: COMPARATOR
Intervention: Open system (OS) suctioning
Number of subjects: 14
Study 9798793 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDA/CA-developed standard intervention (SI)
Number of subjects: 3743
Study 9798793 — intervention group
Group type: EXPERIMENTAL
Intervention: SI plus a site-specific enhanced intervention (EI)
Number of subjects: 3743
Study 7803769 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy with 111In-labeled octreotide
Number of subjects: 40